Solution conformations of the substrates and inhibitor of hepatitis C virus NS3 protease

被引:0
|
作者
Lee, JH
Bang, K
Jung, JW
Ahn, IA
Ro, S
Lee, W
机构
[1] Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120740, South Korea
[2] LG Chem, Biotech Res Inst, Taejon 305380, South Korea
关键词
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Hepatitis C virus (HCV) has been known to be an enveloped virus with a positive strand RNA genome and the major agent of the vast majority of transfusion associated cases of hepatitis. For viral replication, HCV structural proteins are first processed by host cell signal peptidases and NS2/NS3 site of the nonstructural protein is cleaved by a zinc-dependent protease NS2 with N-terminal NS3. The four remaining junctions are cleaved by a separate NS3 protease. The solution conformations of NS4B/5A, NS5A/5B substrates and NS5A/5B inhibitor have been determined by two-dimensional nuclear magnetic resonance (NMR) spectroscopy. NMR data suggested that the both NS5A/5B substrate and inhibitor appeared to have a folded turn-like conformation not only between P1 and P6 position but also C-terminal region, whereas the NS4B/5A substrate exhibited mostly extended conformation. In addition, we have found that the conformation of the NS5A/5B inhibitor slightly differs from that of NS5A/5B substrate peptide, suggesting different binding mode for NS3 protease. These findings will be of importance for designing efficient inhibitor to suppress HCV processing.
引用
收藏
页码:301 / 306
页数:6
相关论文
共 50 条
  • [31] 1-aminocyclopropaneboronic acid: Synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease
    Priestley, ES
    Decicco, CP
    ORGANIC LETTERS, 2000, 2 (20) : 3095 - 3097
  • [32] Affinity selection of a camelized VH domain antibody inhibitor of hepatitis C virus NS3 protease
    Martin, F.
    Volpari, C.
    Steinkuehler, C.
    Dimasi, N.
    Protein Engineering, 10 (05):
  • [33] Correction: Corrigendum: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
    Daniel Lamarre
    Paul C. Anderson
    Murray Bailey
    Pierre Beaulieu
    Gordon Bolger
    Pierre Bonneau
    Michael Bös
    Dale R. Cameron
    Mireille Cartier
    Michael G. Cordingley
    Anne-Marie Faucher
    Nathalie Goudreau
    Stephen H. Kawai
    George Kukolj
    Lisette Lagacé
    Steven R. Laplante
    Hans Narjes
    Marc-André Poupart
    Jean Rancourt
    Roel E. Sentjens
    Roger St George
    Bruno Simoneau
    Gerhard Steinmann
    Diane Thibeault
    Youla S. Tsantrizos
    Steven M. Weldon
    Chan-Loi Yong
    Montse Llinàs-Brunet
    Nature, 2003, 426 : 314 - 314
  • [34] Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy
    Halfon, Philippe
    Bourliere, Marc
    Khiri, Hacene
    Penaranda, Guillaume
    Martineau, Agnes
    Oules, Valerie
    Courcambeck, Jerome
    Philibert, Patrick
    AIDS, 2008, 22 (13) : 1694 - 1696
  • [35] Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C
    Klibanov, Olga M.
    Vickery, Stephen B.
    Olin, Jacqueline L.
    Smith, Lisa S.
    Williams, Shannon H.
    PHARMACOTHERAPY, 2012, 32 (02): : 173 - 190
  • [36] Boceprevir. NS3 protease inhibitor, Treatment of chronic hepatitis C
    Campas, C.
    Pandian, R.
    Bolos, J.
    Castaner, R.
    DRUGS OF THE FUTURE, 2009, 34 (09) : 697 - 707
  • [37] Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C
    Klibanov, Olga M.
    Williams, Shannon H.
    Smith, Lisa S.
    Olin, Jacqueline L.
    Vickery, Stephen B.
    PHARMACOTHERAPY, 2011, 31 (10): : 951 - 974
  • [38] Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir
    Berger, Kristi L.
    Triki, Ibtissem
    Cartier, Mireille
    Marquis, Martin
    Massariol, Marie-Josee
    Boecher, Wulf O.
    Datsenko, Yakov
    Steinmann, Gerhard
    Scherer, Joseph
    Stern, Jerry O.
    Kukolj, George
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (02) : 698 - 705
  • [39] Longer wavelength fluorescence resonance energy transfer depsipeptide substrates for hepatitis C virus NS3 protease
    Konstantinidis, Alex K.
    Richardson, Paul L.
    Kurtz, Kevin A.
    Tripathi, Rakesh
    Chen, Chih-Ming
    Huang, Peggy
    Randolph, John
    Towne, Danli
    Donnelly, Jennifer
    Warrior, Usha
    Middleton, Tim
    Kati, Warren M.
    ANALYTICAL BIOCHEMISTRY, 2007, 368 (02) : 156 - 167
  • [40] Cell transformation induced by hepatitis C virus NS3 serine protease
    Zemel, R
    Gerechet, S
    Greif, H
    Bachmatove, L
    Birk, Y
    Golan-Goldhirsh, A
    Kunin, M
    Berdichevsky, Y
    Benhar, I
    Tur-Kaspa, R
    JOURNAL OF VIRAL HEPATITIS, 2001, 8 (02) : 96 - 102